Design considerations, architecture, and use of the Mini-Sentinel distributed data system - PubMed (original) (raw)
. 2012 Jan:21 Suppl 1:23-31.
doi: 10.1002/pds.2336.
Affiliations
- PMID: 22262590
- DOI: 10.1002/pds.2336
Design considerations, architecture, and use of the Mini-Sentinel distributed data system
Lesley H Curtis et al. Pharmacoepidemiol Drug Saf. 2012 Jan.
Abstract
Purpose: We describe the design, implementation, and use of a large, multiorganizational distributed database developed to support the Mini-Sentinel Pilot Program of the US Food and Drug Administration (FDA). As envisioned by the US FDA, this implementation will inform and facilitate the development of an active surveillance system for monitoring the safety of medical products (drugs, biologics, and devices) in the USA.
Methods: A common data model was designed to address the priorities of the Mini-Sentinel Pilot and to leverage the experience and data of participating organizations and data partners. A review of existing common data models informed the process. Each participating organization designed a process to extract, transform, and load its source data, applying the common data model to create the Mini-Sentinel Distributed Database. Transformed data were characterized and evaluated using a series of programs developed centrally and executed locally by participating organizations. A secure communications portal was designed to facilitate queries of the Mini-Sentinel Distributed Database and transfer of confidential data, analytic tools were developed to facilitate rapid response to common questions, and distributed querying software was implemented to facilitate rapid querying of summary data.
Results: As of July 2011, information on 99,260,976 health plan members was included in the Mini-Sentinel Distributed Database. The database includes 316,009,067 person-years of observation time, with members contributing, on average, 27.0 months of observation time. All data partners have successfully executed distributed code and returned findings to the Mini-Sentinel Operations Center.
Conclusion: This work demonstrates the feasibility of building a large, multiorganizational distributed data system in which organizations retain possession of their data that are used in an active surveillance system.
Copyright © 2012 John Wiley & Sons, Ltd.
Similar articles
- The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.
Platt R, Carnahan RM, Brown JS, Chrischilles E, Curtis LH, Hennessy S, Nelson JC, Racoosin JA, Robb M, Schneeweiss S, Toh S, Weiner MG. Platt R, et al. Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:1-8. doi: 10.1002/pds.2343. Pharmacoepidemiol Drug Saf. 2012. PMID: 22262586 - The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
Robb MA, Racoosin JA, Sherman RE, Gross TP, Ball R, Reichman ME, Midthun K, Woodcock J. Robb MA, et al. Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:9-11. doi: 10.1002/pds.2311. Pharmacoepidemiol Drug Saf. 2012. PMID: 22262587 No abstract available. - A policy framework for public health uses of electronic health data.
McGraw D, Rosati K, Evans B. McGraw D, et al. Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:18-22. doi: 10.1002/pds.2319. Pharmacoepidemiol Drug Saf. 2012. PMID: 22262589 - Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
Trifirò G, Coloma PM, Rijnbeek PR, Romio S, Mosseveld B, Weibel D, Bonhoeffer J, Schuemie M, van der Lei J, Sturkenboom M. Trifirò G, et al. J Intern Med. 2014 Jun;275(6):551-61. doi: 10.1111/joim.12159. J Intern Med. 2014. PMID: 24635221 Review. - A review of complications associated with vertebroplasty and kyphoplasty as reported to the Food and Drug Administration medical device related web site.
Nussbaum DA, Gailloud P, Murphy K. Nussbaum DA, et al. J Vasc Interv Radiol. 2004 Nov;15(11):1185-92. doi: 10.1097/01.RVI.0000144757.14780.E0. J Vasc Interv Radiol. 2004. PMID: 15525736 Review.
Cited by
- Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROmediCAT Study.
de Jonge L, Garne E, Gini R, Jordan SE, Klungsoyr K, Loane M, Neville AJ, Pierini A, Puccini A, Thayer DS, Tucker D, Vinkel Hansen A, Bakker MK. de Jonge L, et al. Drug Saf. 2015 Nov;38(11):1083-93. doi: 10.1007/s40264-015-0321-9. Drug Saf. 2015. PMID: 26153398 Free PMC article. - Artificial Intelligence, Real-World Automation and the Safety of Medicines.
Bate A, Hobbiger SF. Bate A, et al. Drug Saf. 2021 Feb;44(2):125-132. doi: 10.1007/s40264-020-01001-7. Epub 2020 Oct 7. Drug Saf. 2021. PMID: 33026641 - Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.
Toh S, Hampp C, Reichman ME, Graham DJ, Balakrishnan S, Pucino F, Hamilton J, Lendle S, Iyer A, Rucker M, Pimentel M, Nathwani N, Griffin MR, Brown NJ, Fireman BH. Toh S, et al. Ann Intern Med. 2016 Jun 7;164(11):705-14. doi: 10.7326/M15-2568. Epub 2016 Apr 26. Ann Intern Med. 2016. PMID: 27110660 Free PMC article. - Assessment of Quadrivalent Human Papillomavirus Vaccine Safety Using the Self-Controlled Tree-Temporal Scan Statistic Signal-Detection Method in the Sentinel System.
Yih WK, Maro JC, Nguyen M, Baker MA, Balsbaugh C, Cole DV, Dashevsky I, Mba-Jonas A, Kulldorff M. Yih WK, et al. Am J Epidemiol. 2018 Jun 1;187(6):1269-1276. doi: 10.1093/aje/kwy023. Am J Epidemiol. 2018. PMID: 29860470 Free PMC article. - Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance.
Zhang J, Sridhar G, Barr CE, Eichelberger B, Lockhart CM, Marshall J, Clewell J, Accortt NA, Curtis JR, Holmes C, McMahill-Walraven CN, Brown JS, Haynes K. Zhang J, et al. J Manag Care Spec Pharm. 2020 Apr;26(4):417-490. doi: 10.18553/jmcp.2020.26.4.417. J Manag Care Spec Pharm. 2020. PMID: 32223608 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials